Research programme: autologous T-cell therapies - Adaptimmune

Drug Profile

Research programme: autologous T-cell therapies - Adaptimmune

Alternative Names: Affinity-enhanced T-cell receptors - Adaptimmune; Allogenic T-cell therapies - Adaptimmune; Cytotoxic T-lymphocytes stimulants - Adaptimmune; PRAME; Preferentially expressed antigen in melanoma

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adaptimmune
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Immunological disorders
  • No development reported Cancer; Diabetes mellitus; Hepatitis C

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Cancer in United Kingdom (IV, Infusion)
  • 28 May 2018 No recent reports of development identified for research development in Diabetes-mellitus in United Kingdom (Infusion)
  • 28 May 2018 No recent reports of development identified for research development in Hepatitis-C in United Kingdom (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top